Dr. Rosemary Roberts

• 
  media.rampard.com/phemce/20070731/day2.html - [Cached Version]
  Published on: 8/1/2007    Last Visited: 9/14/2008  

  Rosemary Roberts, M.D. Director, Office of Counter-Terrorism and Emergency CoordinationCenter for Drug Evaluation and Research, Food and Drug Administration

• 
  National News Tidbits - [Cached Version]
  Published on: 8/18/2003    Last Visited: 8/25/2003  

  Dr. Rosemary Roberts, a researcher at the Food and Drug Administration, said the findings have led to new drug labeling that outlines potential risks to children.
  
  But she said the program is voluntary and can't answer all questions about the drugs.

• 
  Pediatric Drug Studies: Protecting Pint-Sized Patients... - [Cached Version]
  Published on: 1/30/2004    Last Visited: 6/26/2005  

  "That was the voluntary effort, and we weren't making much headway," says Rosemary Roberts, M.D., chair of the pediatric subcommittee in FDA's Center for Drug Evaluation and Research."Most manufacturers just went back to saying that safety and effectiveness had not been established for children."
  
  Without pediatric data about a drug, Roberts says, doctors are sometimes reluctant to treat a child with it."Some physicians won't even try a drug in a child if they don't have enough information," she says.
  ...
  "It can be a real guessing game as to whether we're treating a child effectively," Roberts says.

• 
  Program: 2nd Annual NPSF Clinical Research Conference - [Cached Version]
  Published on: 5/31/2003    Last Visited: 6/8/2005  

  Rosemary Roberts, MDDeputy Director Office of Counter-Terrorism and Pediatric Drug Development (OCTAP), Center for Drug Evaluation and Research, U S Food and Drug Administration (FDA).Dr. Roberts will address the regulatory challenges created by such research, assess current oversight mechanisms, and consider what gaps in oversight need to be addressed.

• 
  Red Book® Online -- Committee 2003 - [Cached Version]
  Published on: 1/1/2003    Last Visited: 9/13/2008  

  Rosemary Roberts, MD, Food and Drug Administration, Rockville, MD

• 
  Studies report benefits of chiropractic  care for... - [Cached Version]
  Published on: 3/8/2003    Last Visited: 6/18/2004  

  "That was the voluntary effort, and we weren't making much headway," lamented Rosemary Roberts, M.D., chair of the pediatric subcommittee in the FDA's Center for Drug Evaluation and Research.

• 
  Symposium Addresses Ethical Issues - [Cached Version]
  Published on: 3/24/2002    Last Visited: 3/5/2003  

  · Rosemary Roberts, MD, deputy director, Center for Drug Evaluation and Research, Office of Pediatric Drug Development and Program Initiatives; Food and Drug Administration

• 
  The Impact of the FDA Modernization Act on the... - [Cached Version]
  Published on: 7/1/2003    Last Visited: 10/8/2004  

  According to Dr. Rosemary Roberts (2002) FDA's Deputy Director of Pediatric Drug Evaluation, there were only six "significant" label changes for dosing or safety.

• 
  U.S. Departments and Offices - AppliedClinicalTrials - [Cached Version]
  Published on: 12/1/2005    Last Visited: 12/20/2005  

  Rosemary Roberts (301) 827-7777 Director, Office of Counter-Terrorism and Pediatric Drug Development

• 
  What's New At FDA? - [Cached Version]
  Published on: 7/9/2001    Last Visited: 3/3/2002  

  Rosemary Roberts, M.D. Presented at the American College of Toxicology Annual Meeting, November 6, 2001 (February 27)
  
  Crawford Named FDA Deputy Commissioner (February 26)
  
  Presentation by CFSAN Center Director to the Institute of Food Technologists (February 12)
  
  2002 FDA Science Forum: Building a Multidisciplinary Foundation (February 13)
  
  New Guidance Proposed for Financial Disclosure by Advisory Committee Members (February 12)

Page:  1 2